On July 19, 2023 Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, reported its participation in the fifth annual Glioblastoma Awareness Day, July 19, 2023 in Washington, D.C (Press release, Kintara Therapeutics, JUL 19, 2023, View Source [SID1234633316]). Originally introduced to the Senate by a bipartisan group of U.S. senators, the inaugural Glioblastoma Awareness Day took place on July 17, 2019.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are honored to participate in the Glioblastoma (GBM) Awareness Day and to be joined by patients, advocates, physicians, and politicians to continue to raise awareness for GBM research and advancement," said Robert E. Hoffman, the President and CEO of Kintara Therapeutics. "Our lead asset for GBM, VAL-083, is being evaluated in GBM AGILE. Positive findings may be used to support a New Drug Application ("NDA") to the FDA."
The Global Coalition for Adaptive Research Phase 2/3 clinical trial titled Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) is an international, innovative platform study designed to more rapidly identify and confirm effective therapies for patients with glioblastoma through response adaptive randomization and a seamless Phase 2/3 design. The study, conceived by over 130 key opinion leaders, is conducted under a master protocol, allowing multiple therapies or combinations of therapies from different pharmaceutical partners to be evaluated simultaneously. ClinicalTrials.gov Identifier: NCT03970447. A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma – Full Text View – ClinicalTrials.gov